Company intelligence / Profile preview

BioAtla

San Diego, California, United Statesir.beigene.com ↗

Ownership: Public · BCAB
Development stage: Phase 2

Overview

BioAtla is developing multiple CAB-based therapeutics with lead candidates in Phase II/III trials. Mecbotamab vedotin (BA3011) is in Phase II/III for AXL-expressing tumors, Ozuriftamab vedotin (BA3021) is in Phase II for ROR2-expressing tumors, and BA3071 is in Phase II for CTLA-4 positive tumors as of 2024.

Therapeutic areas: Oncology
Modalities: Monoclonal antibodiesAntibody-drug conjugates (ADCs)Cell-based therapeutics
Industry: Biotech

Drug pipeline

19 assets

mecbotamab vedotin

18 more assets in the full pipeline.

Request access →

Financials

Market cap: $2.9M
Total revenue: $6.5M
Enterprise value: $7.2M

Beyond the preview

Go deeper on BioAtla.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BioAtla.

Explore the full profile